GIG CYMRU NHS WALES | Iechyd Cyhoeddus Cymru Public Health Wales

Mae Brechu yn achub bywydau
Vaccination saves lives

NHS Wales Meningococcal B vaccination programme to help prevent gonorrhoea

Visual aid for Healthcare Professionals

New programme effective from July 2025
This information is for sexual health professionals delivering the NHS Meningococcal B (MenB) vaccination programme for the prevention of gonorrhoea.

What's new?

From July 2025, NHS Wales will introduce a routine MenB vaccination programme. This programme will help protect gay, bisexual and other men who have sex with men (GBMSM) who are considered at higher risk of gonorrhoea. The programme follows advice from the Joint Committee on Vaccination and Immunisation (JCVI)[1].

The MenB vaccination should be offered opportunistically, based on an individual risk assessment by a sexual health professional.

Who is eligible for the vaccine to help protect against gonorrhoea?

The vaccine is primarily recommended for GBMSM who are considered at higher risk of infection, which includes GBMSM who:

- have had a bacterial sexually transmitted infection (STI) in the past year, or
- have had five or more sexual partners in the last three months.

Sexual health professionals may offer the vaccine to other individuals with similar risk to the eligible GBMSM, such as sex workers practising condomless sex – regardless of their gender or sexual orientation.

Any offer of vaccination should be based on an individual risk assessment by a sexual health professional.

Which vaccine is recommended?

Bexsero® 4-component serogroup B meningococcal vaccine (4CMenB)

The 4CMenB vaccine is not officially licensed for the prevention of gonorrhoea. However, its off-label use has been recommended by the JCVI to help protect against gonorrhoea.

How does the vaccine work?

Neisseria gonorrhoeae (the bacteria causing gonorrhoea) is closely genetically related to *Neisseria meningitidis* (the bacteria causing meningococcal disease). Therefore, the 4CMenB vaccine offers some cross-protection against gonorrhoea.

How to order

Supply of Bexsero® is available for hospital pharmacies to order on the ImmForm website for delivery to Sexual Health Services.

Dosage

Administer a course of two doses at least four weeks apart. There is no maximum time interval limit between the two vaccine doses. Pragmatically and opportunistically, the second dose can be scheduled for the next clinic attendance, which may be after three, six or 12 months. There is no need to restart the primary immunisation schedule, even after a prolonged interval between the two doses.

Can the vaccine be co-administered?

Yes. The 4CMenB vaccine can be given at the same time as the HPV, mpox, hepatitis A and hepatitis B vaccines. When co-administered, vaccines should be given at separate injection sites, preferably in different limbs. If more than one vaccine is given in the same limb, they should be at least 2.5cm apart. The vaccine is also safe for people living with HIV and those taking PrEP.

How effective is the vaccine?

Recent studies suggest that the 4CMenB vaccine may provide 30-40% protection against gonorrhoea in people at high risk of infection. While individual protection is modest, the primary benefit of the vaccine is that it can help reduce gonorrhoea cases in the community.

Further information

- Public Health Wales – **Meningococcal B vaccination for gonorrhoea: Information for healthcare professionals**
- **Gonorrhoea: the Green Book chapter - GOV.UK (external site)**
- **Introduction of routine vaccinations for mpox and gonorrhoea (WHC/2025/021) | GOV.WALES (external site)**
- **Meningococcal B (MenB) vaccination programme for Gonorrhoea - GOV.UK (external site)**
- Free resources to support vaccination clinics: **Health Information Resources - Public Health Wales**
- Guidance on Patient Group Directions: **Patient Group Directions (PGD) - Welsh Medicines Advice Service (external site)**
- Bexsero ® Summary of product characteristics: **Bexsero Meningococcal Group B vaccine for injection in pre-filled syringe - Summary of Product Characteristics (emc) (external site)**
- **Yellow Card | Making medicines and medical devices safer (external site)**
- **BASHH guidelines (external site)**

References

1. **JCVI advice on the use of meningococcal B vaccination for the prevention of gonorrhoea - GOV.UK (external site)**

Version 1 | July 2025 © Public Health Wales NHS Trust (with acknowledgement to the UK Health Security Agency)

Iechyd Cyhoeddus Cymru
Public Health Wales

Mae Brechu yn achub bywydau
Vaccination saves lives

Rhaglen frechu Meningococol B GIG Cymru i helpu i atal gonoroea

Cymorth gweledol i Weithwyr Gofal Iechyd Proffesiynol

Rhaglen newydd yn dod i rym o fis Gorffennaf 2025
Mae'r wybodaeth hon ar gyfer gweithwyr iechyd rhywiol proffesiynol sy'n cyflwyno rhaglen frechu Meningococol B (MenB) y GIG ar gyfer atal gonoroea.

Beth sy'n newydd?

O fis Gorffennaf 2025 ymlaen, bydd GIG Cymru yn cyflwyno rhaglen frechu MenB arferol. Bydd y rhaglen hon yn helpu i amddiffyn dynion hoyw, deurywiol a dynion eraill sy'n cael rhyw gyda dynion (GBMSM) a ystyrir eu bod mewn mwy o berygl o gonorea. Mae'r rhaglen yn dilyn cyngor gan y Cyd-bwyllgor ar Frechu ac Imiwneiddio (JCVI)[1].

Dylid cynnig y brechlyn MenB pan fo'r cyfle'n codi, yn seiliedig ar asesiad risg unigol gan weithiwr gofal iechyd rhywiol proffesiynol.

Pwy sy'n gymwys i gael y brechlyn i helpu i amddiffyn rhag gonoroea?

Argymhellir y brechlyn yn bennaf ar gyfer GBMSM sy'n cael eu hystyried mewn mwy o berygl o gael eu heintio, sy'n cynnwys GBMSM sydd:

- wedi cael haint bacteriol a drosglwyddir yn rhywiol (STI) yn ystod y flwyddyn ddiwethaf, neu sydd
- wedi cael pump neu fwy o bartneriaid rhywiol yn ystod y tri mis diwethaf.

Gall gweithwyr iechyd rhywiol proffesiynol gynnig y brechlyn i unigolion eraill sydd â risg debyg i'r dynion GBMSM sy'n gymwys, fel gweithwyr rhyw sy'n cael rhyw heb gondom – ni waeth beth fo'u rhyw neu gyfeiriadedd rhywiol.

Dylai cynnig brechiad fod yn seiliedig ar asesiad risg unigol gan weithiwr gofal iechyd rhywiol proffesiynol.

Pa frechlyn sy'n cael ei argymell?

Brechlyn Meningococol serogrŵp B 4-cydran ***Bexsero***® (4CMenB)

Nid yw'r brechlyn 4CMenB wedi'i drwyddedu'n swyddogol ar gyfer atal gonoroea. Fodd bynnag, mae ei ddefnydd oddi ar y label wedi cael ei argymell gan y JCVI i helpu i amddiffyn rhag gonoroea.

Sut mae'r brechlyn yn gweithio?

Mae *Neisseria gonorrhoeae* (y bacteria sy'n achosi gonoroea) yn perthyn yn agos yn enetig i *Neisseria meningitidis* (y bacteria sy'n achosi clefyd Meningococol). Felly, mae'r brechlyn 4CMenB yn cynnig rhywfaint o groesddiogelu yn erbyn gonoroea.

Sut i archebu brechlynnau

Mae cyflenwad o frechlynnau Bexsero® ar gael i fferyllfeydd ysbytai ei archebu ar wefan ImmForm i'w ddanfon i Wasanaethau Iechyd Rhywiol.

Dos

Rhowch gwrs o ddau ddos o leiaf bedair wythnos ar wahân. Nid oes terfyn amser ar gyfer rhoi'r ail ddos o'r brechlyn. Yn bragmatig ac os yw'r cyfle'n codi, gellir trefnu'r ail ddos yn ystod yr ymweliad nesaf â'r clinig, a all fod ar ôl tri, chwech neu 12 mis. Nid oes angen ailddechrau'r amserlen imiwneiddio sylfaenol, hyd yn oed ar ôl cyfnod hir rhwng y ddau ddos.

A ellir cyd-weinyddu'r brechlyn?

Gellir. Gellir rhoi'r brechlyn 4CMenB ar yr un pryd â'r brechlynnau HPV, brech M, hepatitis A a hepatitis B. Pan gânt eu rhoi ar y cyd, dylid rhoi brechlynnau mewn mannau chwistrellu ar wahân, yn ddelfrydol mewn aelodau gwahanol. Os rhoddir mwy nag un brechlyn yn yr un aelod, dylent fod o leiaf 2.5cm oddi wrth ei gilydd. Mae'r brechlyn hefyd yn ddiogel i bobl sy'n byw gyda HIV a'r rhai sy'n cymryd PrEP.

Pa mor effeithiol yw'r brechlyn?

Mae astudiaethau diweddar yn awgrymu y gall y brechlyn 4CMenB ddarparu amddiffyniad o 30% i 40% rhag gonoroea ymysg pobl sydd mewn perygl uchel o gael eu heintio. Er bod amddiffyniad unigol yn gymedrol, prif fantais y brechlyn yw ei fod yn gallu helpu i leihau achosion o gonorea yn y gymuned.

Rhagor o wybodaeth

- Iechyd Cyhoeddus Cymru – **Brechlyn Meningococol B ar gyfer gonoroea: gwybodaeth i weithwyr gofal iechyd proffesiynol**
- **Gonorrhoea: the Green Book chapter - GOV.UK (safle allanol, Saesneg yn unig)**
- **Cyflwyno rhaglenni brechu rheolaidd ar gyfer brech M a gonorea (WHC/2025/021) | GOV.WALES (safle allanol)**
- **Meningococcal B (MenB) vaccination programme for Gonorrhoea - GOV.UK (safle allanol, Saesneg yn unig)**
- Adnoddau am ddim i gefnogi clinigau brechu: **Adnoddau Gwybodaeth Iechyd - Iechyd Cyhoeddus Cymru**
- Cyfarwyddiadau ar Gyfarwyddiadau Grŵp Cleifion: **Cyfarwyddiadau Grŵp Cleifion (PGDs) - Gwasanaeth Cyngor ar Feddyginiaethau Cymru (safle allanol)**
- Bexsero ® Summary of product characteristics: **Bexsero Meningococcal Group B vaccine for injection in pre-filled syringe - Summary of Product Characteristics (emc) (safle allanol, Saesneg yn unig)**
- **Yellow Card | Making medicines and medical devices safer (safle allanol, Saesneg yn unig)**
- **BASHH guidelines (safle allanol, Saesneg yn unig)**

Cyfeiriadau

1. **JCVI advice on the use of meningococcal B vaccination for the prevention of gonorrhoea - GOV.UK (safle allanol, Saesneg yn unig)**

Fersiwn 1 | Gorffennaf 2025 © Ymddiriedolaeth y GIG Iechyd Cyhoeddus Cymru (gyda chydnabyddiaeth I Asiantaeth Diogelwch Iechyd y DU)